Abstract 56

Featuring HIV/HCV coinfected women in the Icona Cohort: epidemiological and clinical aspects according to gender.

A. Cingolani1, P. Cicconi2, G. Taliani3, G. Marchetti2, L. Sighinolfi4, F. Castelli5, G. Cassola6, D. Francisci7, P. Caramello8, L. Nicolini9, M. Puoti10, A. d’Arminio Monforte for Icona Foundation Study Group and Win Study Group

1 Institute of Infectious Diseases, Catholic University, Roma; 2 Department of Health Sciences, Infectious Diseases, Milano; 3 Institute of Infectious Diseases, La Sapienza University, Roma; 4 Infectious Diseases, Ferrara Hospital, Ferrara; 5 Institute of Infectious Diseases, University of Brescia, Brescia; 6 Infectious Diseases Galliera Hospital, Genova; 7 Institute of Infectious Diseases, University of Perugia, Perugia; 8 Infectious Diseases, Amedeo d’Aosta Hospital, Torino; 9 Institute of Infectious Diseases, University of Genova, Genova; 10 Institute of infectious Diseases, Niguarda ca Granda Hospital, Milano

Background: HIV/HCV women represent a significant challenge in terms of management compared to HIV/HCV men. In HCV monoinfection, a possible higher risk of drug toxicity, higher impact of comorbidities and partially different predictors of fibrosis progression have been reported according to gender; data in HIV/HCV are lacking.

Objectives: To describe demographic, epidemiological and clinical characteristics of HIV/HCV women in the cohort. To identify predictors of HIV/HCV status, of liver damage, and HCV-RNA replication according to gender.

Methods: We included patients (pts) in the ICONA cohort with at least 1 HCVAb test available. Characteristics at time of the first HCVAb determination (baseline) were compared in positive (HCV+) and negative (HCV-) pts using X2/Wilcoxon tests, according to gender. Overall, and gender specific factors associated with HCV+ were identified by logistic regression. Further analyses, with gender as variable of interest, were also performed on HCV+ pts with end points: liver damage at baseline (FIB4>3.25) and evidence of HCV replication (HCVRNA+). Prevalence of different HCV genotypes in males and females was also assessed.

Results: 10318 pts were included; 29.2% tested HCV+. The prevalence of HCV among females and males was 29.4% and 30.0% respectively. Characteristics at first HCV+ according to HCV serostatus and gender are shown in table 1. Female gender did not result to be an independent higher risk of HCV+ (AOR 1.2, 95%CI 0.9-1.4, p=.07). Among females, Caucasian race (AOR 4.7, 95%CI 2.1-10.7, p<0.001), IDU (39.4, 95%CI 27.1-57.4, p<0.001) earlier HIV diagnosis 0.9, 95%CI 0.9 -1.0, p<0.001, for 1 year more), calendar year of enrollment (0.9, 95%CI 0.8-0.9, p<0.001, for each year later) were predictive of HCV+; similar factors resulted predictive of HCV+ in males, except for Caucasian race. Among HCV+, % of females with fib4>3.25 at enrollment was significantly lower as compared to males (10.2% vs. 15.3%, p=.0002).

However after adjusting for potential confounders (g1/4; year of enrollment; year of HIV diagnosis; age, HbSAg, IDU, CD4 and HIV-RNA) the protective role of female gender on liver fibrosis was not confirmed (female AOR 0.8, 95%CI 0.4-1.3). Similarly, gender was not protective of HCVRNA+ (female AOR 0.9, 95%CI 0.6-1.3). HCV genotype was available for 37.5% of pts; in 15.8% G1 was found, with no differences according to gender.

Conclusions: Similar risk factors accounted for HCV infection among males and females, mainly related to IDU in earlier years among Caucasians. Among females, mostly in a premenopausal age, a similar degree of fibrosis compared to their male counterpart was found. Thus in HIV/HCV coinfection, gender seems not to represent a protective factor for advanced liver disease and it could suggest that immunosuppression can equalize HCV-specific outcomes in women and men.